Human Metabolome Technologies, Inc.

Equities

6090

JP3794530000

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 17/05/2024 BST			5-day change	1st Jan Change
659 ^JPY	-0.15%		+2.81%	+2.97%

02-14	Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024	CI
2023	Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	CI

Human Metabolome Technologies, Inc. Provides Financial Guidance for the Quarter Ending June 2021

November 11, 2020 at 06:00 am

Human Metabolome Technologies, Inc. provided financial guidance for the quarter ending June 2021. The company expected net sales of JPY 1,200 million, operating profit of JPY 20 million, profit attributable to owners of parent of JPY 10 million and Earnings per share basic of JPY 1.69.

Latest news about Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024	02-14	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	10/08/23	CI
Human Metabolome Technologies, Inc. Announces Year End Dividend for the Year Ended June 30, 2023, Payable on September 7, 2023; Provides Year End Dividend Guidance for the Year Ending June 30, 2024	10/08/23	CI
Human Metabolome Technologies, Inc. Reports Earnings Results for the Nine Months Ended March 31, 2023	12/05/23	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 2023	12/05/23	CI
Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2023	12/05/23	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 30, 2023	14/02/23	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023	11/11/22	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023	10/08/22	CI
Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022	13/05/22	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	14/02/22	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	12/11/21	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Fourth Quarter Ended June 2021	13/08/21	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	13/08/21	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended March 2021	12/05/21	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Second Quarter Ended December 2020	12/02/21	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2021	12/02/21	CI
Human Metabolome Technologies, Inc. Announces Financial Results for the Quarter Ended September 2020	11/11/20	CI
Human Metabolome Technologies, Inc. Provides Financial Guidance for the Quarter Ending June 2021	11/11/20	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2020	14/08/20	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending June 30, 2021	14/08/20	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended March 2020; Provides Earnings Guidance for the Year Ending June 30, 2020	08/05/20	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Second Quarter Ended December 2019; Provides Consolidated Earnings Guidance for the Year Ending June 30, 2020	07/02/20	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending June 2020	14/08/19	CI
Human Metabolome Technologies, Inc. Reports Consolidated Earnings Results for the Six Months Ended December 2018	08/02/19	CI

Chart Human Metabolome Technologies, Inc.

Duration

Period

Chart Human Metabolome Technologies, Inc.

More charts

Company Profile

Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
HUMAN METABOLOME TECHNOLOGIES, INC.	+2.97%	25.08M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research